Public Citizen Statement to the FDA on Pharmacy Compounding Issues Related to Use of Bulk Substances and Office Stock

View as PDF.

In a statement to Food and Drug Administration (FDA) officials during a listening session with consumer groups, Public Citizen urged the FDA to prevent compounding using bulk drug substances that have been identified as unsafe or ineffective by FDA reviewers. We also expressed strong support for the FDA’s proposal to prevent compounding pharmacies from engaging in compounding large quantities of products for sale to healthcare providers as office stock.